Payment overview · 2025
General Payments
$153.41
8 reported records · 5 companies
Healthcare provider profile · identity verified
Timothy Gatz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KALAMAZOO, MI · NPI 1689780231
Verified facts
What the public records show
CMS Open Payments records show Timothy Gatz, MD received $153.41 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.57 | 32.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.96 | 31.9% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.45 | 16.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.73 | 10.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.70 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.41 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 625 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 592 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 526 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 486 | 142 |
| Lisinopril | Lisinopril | 406 | 109 |
| Omeprazole | Omeprazole | 370 | 108 |
| Gabapentin | Gabapentin | 357 | 78 |
| Metformin Hcl | Metformin Hcl | 306 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 281 | 43 |
| Simvastatin | Simvastatin | 275 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 69 |
| Metformin Hcl Er | Metformin Hcl | 229 | 64 |
| Alprazolam | Alprazolam | 218 | 45 |
| Losartan Potassium | Losartan Potassium | 213 | 62 |
| Eliquis | Apixaban | 180 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 48 |
| Sertraline Hcl | Sertraline Hcl | 171 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 30 |
| Trazodone Hcl | Trazodone Hcl | 166 | 43 |
| Allopurinol | Allopurinol | 155 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 52 |
| Furosemide | Furosemide | 149 | 44 |
| Carvedilol | Carvedilol | 138 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 42 |
| Celecoxib | Celecoxib | 131 | 34 |
| Valsartan | Valsartan | 129 | 35 |
| Glimepiride | Glimepiride | 128 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 34 |
| Tramadol Hcl | Tramadol Hcl | 121 | 20 |
| Finasteride | Finasteride | 118 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 34 |
| Atenolol | Atenolol | 105 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 99 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 26 |
| Potassium Chloride | Potassium Chloride | 91 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 18 |
| Trulicity | Dulaglutide | 90 | 18 |
| Montelukast Sodium | Montelukast Sodium | 87 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 26 |
| Famotidine | Famotidine | 82 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 22 |
| Prednisone | Prednisone | 78 | 52 |
| Mounjaro | Tirzepatide | 77 | 11 |
| Ozempic | Semaglutide | 76 | 15 |
| Ezetimibe | Ezetimibe | 74 | 21 |
| Meloxicam | Meloxicam | 73 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 17 |
| Glipizide Er | Glipizide | 67 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 62 | 15 |
| Pregabalin | Pregabalin | 60 | 12 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | 14 |
| Alendronate Sodium | Alendronate Sodium | 57 | suppressed |
| Jardiance | Empagliflozin | 55 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 15 |
| Torsemide | Torsemide | 54 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 18 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Ibuprofen | Ibuprofen | 53 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | 14 |
| Azithromycin | Azithromycin | 48 | 24 |
| Bupropion Xl | Bupropion Hcl | 46 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 26 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate | 40 | 11 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 38 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Mirtazapine | Mirtazapine | 36 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 34 | suppressed |
| Estradiol | Estradiol | 34 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 11 |
| Ketoconazole | Ketoconazole | 31 | 16 |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 14 |
| Ramipril | Ramipril | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 15 |
| Amoxicillin | Amoxicillin | 25 | 16 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 17 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Triazolam | Triazolam | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lunesta | Eszopiclone | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.41 · 8 records | Novo Nordisk Inc | AIRSUPRA, BEXSERO, ELIQUIS, Ozempic, PEDIARIX, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error